FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

_			
ashington.	D.C.	20549	

ton, D.C. 20549	OMB APPROVAL
	UNID APPROVAL

3235-0287				
ı				
0.5				

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Sullivan Lara					2. Issuer Name <b>and</b> Ticker or Trading Symbol Pyxis Oncology, Inc. [ PYXS ]							Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) (First) (Middle) C/O PYXIS ONCOLOGY, INC.					3. Date of Earliest Transaction (Month/Day/Year) 03/26/2024							X Officer (give title Other (specify below)  Chief Executive Officer					
321 HARRISON AVENUE, 11TH FL. SUITE 1					4. If Amendment, Date of Original Filed (Month/Day/Year)						I	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
(Street) BOSTO	N M	IA	02118	-	Rule 10b5-1(c) Transaction Indication						Form filed by More than One Reporting Person						
(City)	(S	State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transac Date (Month/Da	Execution Date		Code (Instr.		red (A) or str. 3, 4 and 5)	5. Amour Securities Beneficia Owned F Reported		Form: (D) or		7. Nature of ndirect Beneficial Dwnership Instr. 4)				
						Code	/ Amoun	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)				1150. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Securitie Derivativ	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (Right to Buy)	\$3.83	03/26/2024		A		1,071,242		(1)	03/26/2034	Common Stock	1,071,242	\$3.83	1,071,2	242	D		

## **Explanation of Responses:**

1. The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 26, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

/s/ Pamela Connealy, Attorneyin-Fact for Lara Sullivan

03/28/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.